|Merus N.V. to participate in Webcast on Making a name in cancer immunotherapy|
Utrecht, The Netherlands— June 2017 —Ton Logtenberg, Founder and Chief Executive Officer of Merus N.V. will participate in a BioPharma Dealmakers webcast, sponsored in part by Merus N.V., featuring three other companies innovating cancer immunotherapy. The webcast, part of the BioPharma Dealmakers series, is scheduled for 5:00 pm CEST on June 13th.
> Webcast registration link
The webcast will conclude with a live roundtable discussion and a Q&A section to allow you to participate and put your own questions to the speakers.
Prof. Logtenberg previously founded U-BiSys, a biotechnology company that merged with IntroGene to become the publicly-listed company Crucell. In 2006, Logtenberg founded and became the CEO of Merus NV, a Nasdaq-listed biotechnology company based in both the Netherlands and the US, focusing on human bispecific antibodies based on the full length IgG format for the treatment of cancer patients.
Other webcast participants include:
About the Webcast
About Merus N.V.
Merus is a clinical-stage immuno-oncology company developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics®. Biclonics® are based on the full-length IgG format, are manufactured using industry standard processes and have been observed in preclinical studies to share several features of conventional monoclonal antibodies, such as long half-life and low immunogenicity. Merus' lead bispecific antibody candidate, MCLA-128, is being evaluated in a Phase 1/2 clinical trial in Europe as a potential treatment for HER2-expressing solid tumors. Merus' second bispecific antibody candidate, MCLA-117, is being developed in a Phase 1 clinical trial in patients with acute myeloid leukemia. The Company also has a pipeline of proprietary bispecific antibody candidates in preclinical development, including MCLA-158, which is designed to bind to cancer stem cells and is being developed as a potential treatment for colorectal cancer and other solid tumors, as well as Biclonics® designed to bind to various combinations of immunomodulatory molecules, including PD-1 and PD-L1.